BioDir 产业动态
699 条内容- ▶ FDA代理局长被免，礼来三靶点药再胜 2026-05-23
- ▶ 帕拉比利斯IPO前夕获再生元23亿美元合作 2026-05-22
- ▶ FDA终批吉利德丁肝药 2026-05-22
- ▶ 胆固醇运输酶或成癌症治疗新靶点 2026-05-22
- ▶ AI设计破解GPCR药物难题 2026-05-22
- ▶ 含功能性神经的人肠道类器官实现量产 2026-05-22
- ▶ 美议员促限制对华生物技术投资 2026-05-22
- ▶ 2026年前5月生物制药融资盘点 2026-05-22
- ▶ 生物制药融资额趋势分析 2026-05-22
- ▶ 阿斯利康乳腺癌药获欧盟支持，与FDA意见分歧 2026-05-22
- ▶ 犹他州AI处方实验进展如何？ 2026-05-22
- ▶ AI科学家、股市震荡与专利诉讼 2026-05-22
- ▶ Oorja获3000万美元推进IPF药物 2026-05-22
- ▶ FDA四月批准14款新药，礼来口服GLP-1获里程碑 2026-05-22
- ▶ EMA推荐批准勃林格肺病新药Jascayd 2026-05-22
- ▶ MEK抑制剂联合化疗胰腺癌OS达17.3个月 2026-05-22
- ▶ 生物医药行业人事变动汇总 2026-05-22
- ▶ 2026年5月22日融资汇总 2026-05-22
- ▶ 2026年5月22日监管动态 2026-05-22
- ▶ 2026年5月22日临床要闻 2026-05-22
- ▶ 大熊制药接手Turn Bio长寿平台 2026-05-22
- ▶ 中国新规严管IIT，消除灰色市场 2026-05-22
- ▶ 阵亡将士纪念日休刊通知 2026-05-22
- ▶ 2026年5月22日生物医药速览 2026-05-22
- ▶ ASCO26前瞻：五大药企癌症数据抢先看 2026-05-22
- ▶ FDA批准Datroway用于三阴性乳腺癌一线治疗 2026-05-22
- ▶ Recordati面临要约收购，Sobi痛风药Ⅲ期成功 2026-05-22
- ▶ EMA有望批准勃林格肺病新药Jascayd 2026-05-22
- ▶ 百健与Denali帕金森病药物中期试验失败 2026-05-22
- ▶ 健康AI独角兽为何免费开放服务 2026-05-22
- ▶ 诺华寻求拓展Avidity技术至肌营养不良以外疾病 2026-05-22
- ▶ BioWorld Science假期停刊通知 2026-05-22
- ▶ Ignis Therapeutics 新型M4受体PAMs 2026-05-22
- ▶ 韩美药业公布新型YAP1/TEAD抑制剂 2026-05-22
- ▶ 迈诺威医药获PD-1/PD-L1抑制剂专利 2026-05-22
- ▶ Selection发现新型Kv1.3阻断剂 2026-05-22
- ▶ 月经‘足迹’或成健康指标 2026-05-22
- ▶ 辉瑞专利详述TREM2激动剂 2026-05-22
- ▶ 双靶向CAR T联合雷帕霉素治疗多发性骨髓瘤 2026-05-22
- ▶ Sangamo展示朊病毒抑制剂ST-506灵长类数据 2026-05-22
- ▶ AT-108：重编程肿瘤细胞为树突状细胞的免疫疗法 2026-05-22
- ▶ AVB-406基因疗法靶向MAPT治疗阿尔茨海默病 2026-05-22
- ▶ 复宏汉霖三抗HLX-3902获澳临床试验许可 2026-05-22
- ▶ 新型PARP1/2-端锚聚合酶抑制剂优于第一代 2026-05-22
- ▶ Scribe CRISPR疗法STX-1150获批临床 2026-05-22
- ▶ 百健与丹纳利帕金森病药物中期试验失败 2026-05-22
- ▶ ASCO 2026：VEGF双抗竞争升温，TROP2 ADC数据亮眼 2026-05-22
- ▶ 安进CFO下月退休，再鼎高管离职 2026-05-22
- ▶ AI设计迷你蛋白开关靶向GPCR 2026-05-21
- ▶ #ASCO26：默克合作伙伴科伦报告肺癌III期成功 2026-05-21
- ▶ #ASCO26：强生等公司公布头颈癌关键数据 2026-05-21
- ▶ ASCO 2026：VEGF双抗新数据亮相 2026-05-21
- ▶ Bio-IT World 25周年聚焦罕见病挑战 2026-05-21
- ▶ 细胞因子武装CAR T细胞攻克脑瘤异质性 2026-05-21
- ▶ AI绘制基因协作地图 2026-05-21
- ▶ 生物技术公司秘密推动FDA局长下台 2026-05-21
- ▶ Wacker推出核酸疗法合同研究服务 2026-05-21
- ▶ IVL技术竞争白热化，Shockwave力保领先 2026-05-21
- ▶ AI与远程医疗重塑澳大利亚医疗科技 2026-05-21
- ▶ Apellis因Biogen交易大涨，但生物制药指数跑输市场 2026-05-21
- ▶ Tennor香港IPO募资8000万美元推进抗菌药管线 2026-05-21
- ▶ 礼来三重G激动剂再获成功 2026-05-21
- ▶ Infex呼吸道感染药物IIa期临床成功 2026-05-21
- ▶ 生物医药行业人事变动：5月21日 2026-05-21
- ▶ 5月21日生物医药行业动态简报 2026-05-21
- ▶ 2026年5月21日融资动态 2026-05-21
- ▶ 5月21日全球生物医药监管动态 2026-05-21
- ▶ 2026年5月21日临床简报 2026-05-21
- ▶ 埃博拉疫情持续报道 2026-05-21
- ▶ RA Capital为生物科技SPAC融资7500万美元 2026-05-21
- ▶ 中国药企亮相ASCO2026 2026-05-21
- ▶ BioMarin关键试验成功，有望扩大畅销药适应症 2026-05-21
- ▶ 礼来三重G激动剂减肥试验成功 2026-05-21
- ▶ BioMarin 寻求扩大 Voxzogo 用于特定身材矮小 2026-05-21
- ▶ Incyte签下两项AI合作 2026-05-21
- ▶ 诊断与生物信息学助力埃博拉疫情评估 2026-05-21
- ▶ 礼来三靶点减肥药3期达标 2026-05-21
- ▶ BMS考虑在得州建新园区，诺华欲驱逐斯洛文尼亚租户 2026-05-21
- ▶ Gertrude Biomedical 发现新型 SOX18 抑制剂 2026-05-21
- ▶ BMS押注阿尔茨海默病，挑战淀粉样蛋白理论 2026-05-21
- ▶ Gertrude Biomedical发现新型SOX8抑制剂 2026-05-21
- ▶ 南京瑞居生物公开Nampt激活剂专利 2026-05-21
- ▶ Aevisbio获靶向cereblon新化合物专利 2026-05-21
- ▶ Cereno Scientific将研究CS-585治疗抗磷脂综合征 2026-05-21
- ▶ Recludix推出新型STAT1/3抑制剂治疗皮肤病 2026-05-21
- ▶ 豪森药业发现新型PI3Kα突变抑制剂 2026-05-21
- ▶ Nextgen发现新型S1P1/S1P4受体拮抗剂 2026-05-21
- ▶ Ichnos Glenmark 公布实体瘤候选药物 ISB-2301 2026-05-21
- ▶ RPT-E-037双靶点策略对抗胰腺癌 2026-05-21
- ▶ 启函生物CAR-T疗法QT-019C获FDA临床批准 2026-05-21
- ▶ 揭秘X因子：EPAC2改变脆性X治疗格局 2026-05-21
- ▶ 礼来三重激动剂领跑晚期肥胖药 2026-05-21
- ▶ 富士胶片细胞动力威斯康星新总部揭幕 2026-05-20
- ▶ CDD与礼来合作加速生物技术创新 2026-05-20
- ▶ HELIX AI模型精准预测RNA剪接 2026-05-20
- ▶ cAMPfield融资1.8亿美元，主攻免疫炎症药物 2026-05-20
- ▶ 中国将诞生首家跨国制药巨头 2026-05-20
- ▶ GLP-1药物重塑药企与消费者关系 2026-05-20
- ▶ 细胞治疗生产标准化迎来技术革新 2026-05-20
- ▶ 抗体突变优化药物偶联生产 2026-05-20
- ▶ 混合现实发酵模拟器助力生物制造培训 2026-05-20
- ▶ 生物制造重塑器官移植 2026-05-20
- ▶ 联邦巡回法院明确专利许可诉讼资格 2026-05-20
- ▶ Immunovant因RA新药数据飙升35% 2026-05-20
- ▶ 埃博拉疫情拉响国际警报 2026-05-20
- ▶ SEC终结50年“不承认不否认”和解政策 2026-05-20
- ▶ Allegra在女性TAVR患者中表现更优 2026-05-20
- ▶ Champion-AF试验显示年龄不影响LAAC疗效 2026-05-20
- ▶ FDA批准新一代液体活检推进癌症精准诊断 2026-05-20
- ▶ 恒瑞与BMS交易：中国生物技术里程碑 2026-05-20
- ▶ 2026年5月20日行业人事动态 2026-05-20
- ▶ 2026年5月20日监管动态 2026-05-20
- ▶ 2026年5月20日生物医药简讯 2026-05-20
- ▶ 2026年5月20日生物医药融资动态 2026-05-20
- ▶ 2026年5月20日临床动态 2026-05-20
- ▶ Parabilis融资8亿美元后申请IPO 2026-05-20
- ▶ 百时美施贵宝与Anthropic达成AI合作 2026-05-20
- ▶ Acceleron老将创办Oorja，开发肺纤维化新药 2026-05-20
- ▶ 辉瑞新一代肺炎疫苗优于Prevnar 20 2026-05-20
- ▶ Immunovant因RA新药数据上涨 2026-05-20
- ▶ Immunovant关节炎新药潜力巨大 2026-05-20
- ▶ 胎儿基因治疗进展引发胚胎编辑争议 2026-05-20
- ▶ 北京泰德制药合成新型AT2受体拮抗剂 2026-05-20
- ▶ 英矽智能发现新型双靶点FAK抑制剂 2026-05-20
- ▶ 上海药物所与烟台新药创制联合开发新型DAC 2026-05-20
- ▶ 浙师大发现新型RET抑制剂 2026-05-20
- ▶ Re-Aim Therapeutics 获700万英镑种子轮融资 2026-05-20
- ▶ 罗氏公布新型TREM2激动剂 2026-05-20
- ▶ Claromers有望对抗EB病毒 2026-05-20
- ▶ Matter Bio提交PDAC疗法IND申请 2026-05-20
- ▶ Dropshot推进肾脏靶点至临床 2026-05-20
- ▶ Genescience展示新型STAT6降解剂治疗特应性皮炎 2026-05-20
- ▶ Mekanistic的PI3K/EGFR抑制剂获批临床 2026-05-20
- ▶ “去靶向”基因疗法增强庞贝病疗效 2026-05-20
- ▶ 基因细胞疗法缓解弗里德赖希共济失调 2026-05-20
- ▶ Parabilis在Regeneron交易后次日披露IPO计划 2026-05-20
- ▶ GHO Capital与CBC合并，或成最大医疗专业投资者 2026-05-20
- ▶ 礼来收购Engage，推进非病毒基因药物 2026-05-20
- ▶ 再生元与Parabilis达成23亿美元抗体-肽合作 2026-05-20
- ▶ 高尔基体蛋白对决定致癌信号强度 2026-05-19
- ▶ 肠道细菌的“赌注对冲”策略 2026-05-19
- ▶ TrumpRx新增600余种仿制药 2026-05-19
- ▶ Kraig Biocraft Labs制造永生化丝腺细胞系 2026-05-19
- ▶ Paragon再推反向并购，偏头痛新药公司上市 2026-05-19
- ▶ Acceleron前高管携手Westlake成立IPF新药公司 2026-05-19
- ▶ 谷歌DeepMind与Edison打造AI科学家 2026-05-19
- ▶ AI代理挑战科学方法 2026-05-19
- ▶ 体内CAR技术新锐获1.22亿美元B轮融资 2026-05-19
- ▶ 2026年5月19日行业人事变动 2026-05-19
- ▶ 2026年5月19日监管动态 2026-05-19
- ▶ 5月19日生物医药融资动态 2026-05-19
- ▶ 5月19日临床进展一览 2026-05-19
- ▶ SEC推新规重振IPO市场 2026-05-19
- ▶ Elixir Dynamx系统降低心血管事件率 2026-05-19
- ▶ 波科Seismiq IVL临床研究结果积极 2026-05-19
- ▶ Relay的zovegalisib在血管异常II期试验中奏效 2026-05-19
- ▶ 美CDC疫苗顾问委员会获重建 2026-05-19
- ▶ AI代理准备接管科学方法 2026-05-19
- ▶ 最高法院维持FCA举报条款合宪 2026-05-19
- ▶ 2026年5月19日行业简报 2026-05-19
- ▶ 医疗设备迈向智能自适应时代 2026-05-19
- ▶ 美中会谈：生命科学合作机遇 2026-05-19
- ▶ Degron完成4000万美元A轮融资 2026-05-19
- ▶ 2026年初生物医药交易额飙升 2026-05-19
- ▶ 大熊制药6625亿韩元引进IBD新药 2026-05-19
- ▶ Vincentage口服GLP-1药物III期达标 2026-05-19
- ▶ 复星47亿美元押注阿尔茨海默病新药 2026-05-19
- ▶ WHO宣布埃博拉疫情为国际突发公卫事件 2026-05-19
- ▶ BioMarin收购药罕见病研究未达终点 2026-05-19
- ▶ 消费者健康现状 2026-05-19
- ▶ 诺和诺德研发主管：精简研发加速发现 2026-05-19
- ▶ Wave RNA编辑疗法有望每月给药 2026-05-19
- ▶ 偏头痛药企通过反向合并上市 2026-05-19
- ▶ Relay的zovegalisib在血管畸形II期试验中成功 2026-05-19
- ▶ Full-Life筹1.5亿美元，Quince获新生 2026-05-19
- ▶ Korro Bio选出AATD新候选药物 2026-05-19
- ▶ Kimia Therapeutics获得新型DHX9抑制剂专利 2026-05-19
- ▶ 上海美越生物披露新型EHMT2抑制剂 2026-05-19
- ▶ 三嗪类双靶点抑制剂或成三阴性乳腺癌新疗法 2026-05-19
- ▶ Prelude Therapeutics公布新型PROTAC化合物 2026-05-19
- ▶ BCX-17725：Netherton综合征新疗法 2026-05-19
- ▶ KAT6抑制剂SYH-2095获中国临床批准 2026-05-19
- ▶ 康沃生命发现新型CFB抑制剂 2026-05-19
- ▶ Iksuda与UCL开发新型B7-H3靶向ADC 2026-05-19
- ▶ 双载荷ADC展现HER2阳性肿瘤治疗潜力 2026-05-19
- ▶ TOP2B上调驱动心脏毒性，ASO疗法可预防 2026-05-19
- ▶ 本迪布焦埃博拉疫情敲响疫苗策略警钟 2026-05-19
- ▶ 首创STAT6抑制剂对特应性皮炎有效 2026-05-19
- ▶ Relay新药早期显效，或优于诺华疗法 2026-05-19
- ▶ 虚拟营养护理平台Nourish获1亿美元融资 2026-05-19
- ▶ 2026年5月19日融资快讯 2026-05-19
- ▶ 亚太生物医药动态：5月19日简报 2026-05-19
- ▶ 亚太生物医药人事变动速览 2026-05-19
- ▶ 2026年5月19日亚太监管动态 2026-05-19
- ▶ 亚太临床动态：多家公司发布新数据 2026-05-19
- ▶ Relay的PI3Kα抑制剂在血管畸形II期研究达效 2026-05-19
- ▶ BioMarin罕见病疗法3期试验未达终点 2026-05-19
- ▶ 密码子优化不均：基因设计基准测试助力抗体表达 2026-05-19
- ▶ 转录组分析揭示MS髓鞘丢失机制 2026-05-18
- ▶ 脆性X综合征药物靶点被发现 2026-05-18
- ▶ 器官芯片技术揭秘糖尿病与痴呆症关联 2026-05-18
- ▶ Amgen坚持Tavneos安全，日本报告肝毒性 2026-05-18
- ▶ 议员公开FDA未发布新冠疫苗死亡报告 2026-05-18
- ▶ 生物制药融资额变化趋势 2026-05-18
- ▶ 2026年生物制药融资盘点 2026-05-18
- ▶ FDA批准阿斯利康新型降压药 2026-05-18
- ▶ 卡西迪初选失利加剧科学决策不确定性 2026-05-18
- ▶ 美最高法院驳回多家生物制药公司对IRA的挑战 2026-05-18
- ▶ 高血压新药Baxfendy获FDA批准 2026-05-18
- ▶ 再生元Fianlimab黑色素瘤折戟，23亿收购Parabilis 2026-05-18
- ▶ 本地布焦疫情警示广谱疫苗策略的必要性 2026-05-18
- ▶ 5月18日生物医药简讯 2026-05-18
- ▶ 5月18日生物医药人事变动 2026-05-18
- ▶ 2026年5月18日融资动态 2026-05-18
- ▶ 5月18日监管动态：Sandoz与Valar Labs 2026-05-18
- ▶ 临床进展速览：2026年5月18日 2026-05-18
- ▶ Degron 完成 4000 万美元 A 轮融资 2026-05-18
- ▶ 医疗科技并购热潮持续，4月交易额达190亿美元 2026-05-18
- ▶ 波士顿科学15亿美元入股Mirus，获TAVR系统选择权 2026-05-18
- ▶ 默克中国授权ADC首战告捷 2026-05-18
- ▶ 再生元1.25亿美元布局难成药靶点 2026-05-18
- ▶ 本周生物医药要闻回顾 2026-05-18
- ▶ Baxfendy获批，高血压治疗新选择 2026-05-18
- ▶ 生物制药股周涨跌榜 2026-05-18
- ▶ Design Therapeutics发布弗里德赖希共济失调新药数据 2026-05-18
- ▶ FDA再掀人事变动，安进药物致死20人 2026-05-18
- ▶ 默克ADC新药Ⅲ期试验提前报捷 2026-05-18
- ▶ 最高法院不受理制药商IRA诉讼 2026-05-18
- ▶ Mirati公司专利公开新型SOS1抑制剂 2026-05-18
- ▶ Neurolambda Therapeutics公布新型TYK2抑制剂 2026-05-18
- ▶ Nxera Pharma发现新型GPR17拮抗剂 2026-05-18
- ▶ 首药控股公布新型RET抑制剂 2026-05-18
- ▶ 新型放射性标记化合物有望用于癌症诊疗 2026-05-18
- ▶ LET-003肥胖治疗潜力获临床前数据支持 2026-05-18
- ▶ RPE干细胞疗法进入IND研究阶段 2026-05-18
- ▶ CD94靶向CAR-T疗法获临床许可 2026-05-18
- ▶ 基因疗法GPX-002恢复糖尿病β细胞功能 2026-05-18
- ▶ AAV递送PICK1抑制剂缓解小鼠慢性疼痛 2026-05-18
- ▶ AIG-07025展现BRCA/HRD癌症治疗潜力 2026-05-18
- ▶ KC-1101：TACC3阳性肿瘤的同类最佳潜力 2026-05-18
- ▶ 再生元免疫组合疗法黑色素瘤试验失利 2026-05-18
- ▶ 再生元LAG-3抑制剂晚期皮肤癌试验失败 2026-05-18
- ▶ FDA批准阿斯利康高血压新药baxdrostat 2026-05-18
- ▶ 战略外包释放成熟药品价值 2026-05-18
- ▶ Regenxbio基因疗法数据积极但股价大跌 2026-05-18
- ▶ 世卫组织宣布埃博拉疫情为国际突发公共卫生事件 2026-05-17
- ▶ FDA局长马卡里辞职 2026-05-16
- ▶ FDA药物中心主任霍格预计离职 2026-05-15
- ▶ RAGE受体关联衰老与乳腺癌转移 2026-05-15
- ▶ ALS多组学研究揭示免疫浸润机制 2026-05-15
- ▶ 生物制药并购强劲，大型交易减少 2026-05-15
- ▶ 安进加强340B计划监管 2026-05-15
- ▶ 基因治疗融资回暖 2026-05-15
- ▶ 5月15日生物医药简报 2026-05-15
- ▶ 生物医药行业人事变动汇总 2026-05-15
- ▶ 研究关注：Biopharma deal and M&A values soar in early 2026 2026-05-15
- ▶ 研究关注：Validity of Actelion patent hinges on temperature 2026-05-15
- ▶ 研究关注：EU reaches Critical Medicines Act pact to tackle drug shortages 2026-05-15
- ▶ 研究关注：Sonomind raises €20M for ultrasound neuromodulation technology 2026-05-15
- ▶ 研究关注：Authorities work to quickly sequence Ebola strain in latest outbreak 2026-05-15
- ▶ 5月15日临床试验快报 2026-05-15
- ▶ 2026年5月15日生物医药融资汇总 2026-05-15
- ▶ 2026年5月15日监管动态 2026-05-15
- ▶ 研究关注：FDA hold puts Aardvark Prader-Willi drug in limbo 2026-05-15
- ▶ 研究关注：Supreme Court preserves access to abortion pill by mail 2026-05-15
- ▶ 研究关注：Biotech leaders campaign for Pazdur; Takeda to lay off 4,500 workers 2026-05-15
- ▶ 研究关注：Candel reports prostate cancer drug's long-term data ahead of FDA filing 2026-05-15
- ▶ 研究关注：Post-Hoc Live: Makary's out at FDA and what comes next 2026-05-15
- ▶ 研究关注：Authorities work to quickly sequence Ebola strain in latest outbreak 2026-05-15
- ▶ 研究关注：Aardvark's next move after clinical hold; Alumis' verdict on Acelyrin asset 2026-05-15
- ▶ 研究关注：ASGCT 2026: Beverly Davidson Offers Vehicle and Route for Huntington’s Disease Gene Therapy 2026-05-15
- ▶ 研究关注：ASGCT 2026: AI-Optimized Cas12l Gene Editor Offers Compact Cas9 Alternative 2026-05-15
- ▶ 研究关注：India’s pharma industry is going global. But can it catch up to China? 2026-05-15
- ▶ 研究关注：HCW Biologics’ HCW11-040 prevents bronchopulmonary dysplasia 2026-05-15
- ▶ 研究关注：Ensem’s ETX-929 is candidate for KRAS mutant tumors 2026-05-15
- ▶ 研究关注：KSI-028 suppresses STING-driven inflammation 2026-05-15
- ▶ 研究关注：New KRAS mutant inhibitors reported in Université de Montréal patent 2026-05-15
- ▶ 研究关注：NTX-819, a novel mGlu7 NAM for psychiatric disorders 2026-05-15
- ▶ 研究关注：Antelope Therapeutics patents new antibody-drug conjugates for cancer 2026-05-15
- ▶ 研究关注：Maipl Therapeutics advances MA-4604 for endometriosis 2026-05-15
- ▶ 研究关注：Hangzhou Institute of Medicine discovers new CDK2/cyclin E1 inhibitors 2026-05-15
- ▶ 研究关注：Camp4 studies CMP-002 in SYNGAP1 haploinsufficient mouse model 2026-05-15
- ▶ 研究关注：Financing at Create Medicines to advance in vivo CAR therapies 2026-05-15
- ▶ 研究关注：Sanofi identifies YAP1/TEAD and TAZ/TEAD interaction inhibitors 2026-05-15
- ▶ 研究关注：ZMS-4084 shows robust antitumor efficacy in MSI-H cancer models 2026-05-15
- ▶ 研究关注：ASGCT 2026: Directed evolution in gene therapy 2026-05-15
- ▶ 研究关注：CSPC Megalith Biopharmaceutical discloses new CDCP1-targeting ADCs 2026-05-15
- ▶ 研究关注：Launch of CGTxchange to reactivate cell and gene therapy programs 2026-05-15
- ▶ 研究关注：ASGCT 2026: Rare Instance of AAV Integration into Human Genome Linked to Brain Tumor 2026-05-15
- ▶ 研究关注：M&A isn’t just for big pharma. Mid-size companies are stepping up deal hunts 2026-05-15
- ▶ 研究关注：Andrea Pfeifer ends 23-year reign at AC Immune; Acadia's top R&D exec announces retirement 2026-05-15
- ▶ 研究关注：#ASGCT26: A Zillow-like marketplace for abandoned gene therapies goes live 2026-05-15
- ▶ 研究关注：DNA‑Guided CRISPR Suggests a New Direction for RNA Editing 2026-05-15
- ▶ 研究关注：Supreme Court preserves mail access for abortion pill 2026-05-15
- ▶ 研究关注：Implantable Living Materials Contain Infection-Sensing Bacteria That Release Therapeutics 2026-05-14
- ▶ 研究关注：Molecular Anchors Help Tumor Therapies Stay Longer on Cancer Cells 2026-05-14
- ▶ 研究关注：Create Medicines raises $122M to bolster in vivo CAR-T therapies 2026-05-14
- ▶ 研究关注：USPTO doubles down on inconsistencies in dual IPR-court action 2026-05-14
- ▶ 研究关注：Biogen AD drug shows tau, cognition benefit, despite trial miss 2026-05-14
- ▶ 研究关注：Andes virus cases rise to 11; Hondius passengers in quarantine to June 21 2026-05-14
- ▶ 研究关注：Will FDA show Affinity for fast yes to Regenxbio in DMD? 2026-05-14
- ▶ 研究关注：Medical devices evolving into intelligent, adaptive systems 2026-05-14
- ▶ 研究关注：Regulatory actions for May 14, 2026 2026-05-14
- ▶ 研究关注：In the clinic for May 14, 2026 2026-05-14
- ▶ 研究关注：Financings for May 14, 2026 2026-05-14
- ▶ 研究关注：Other news to note for May 14, 2026 2026-05-14
- ▶ 研究关注：Appointments and advancements for May 14, 2026 2026-05-14
- ▶ 研究关注：Fosun secures rights to Aribio’s AR-1001 in potential $4.7B deal 2026-05-14
- ▶ 研究关注：Fosun secures rights to Aribio’s AR-1001 in potential $4.7B deal 2026-05-14
- ▶ 研究关注：Biogen pushing tau drug forward despite Alzheimer’s study failure 2026-05-14
- ▶ 研究关注：With new data, Regenxbio to seek FDA approval of Duchenne gene therapy 2026-05-14
- ▶ 研究关注：ASGCT 2026: Uncovering the mechanisms of AAV toxicity 2026-05-14
- ▶ 研究关注：Vivozon reports new dual 5-HT2A/dopamine D2 receptor antagonists 2026-05-14
- ▶ 研究关注：Pfizer discloses new dual calcitonin/amylin receptor agonists 2026-05-14
- ▶ 研究关注：KHN-921 gains IND clearance for MYBPC3 -associated HCM 2026-05-14
- ▶ 研究关注：Epirium’s 15-PGDH inhibitor IBD candidates improve disease outcomes in models 2026-05-14
- ▶ 研究关注：Blueprint’s BLU-448, a CDK4 degrader for HR+/HER2- breast cancer 2026-05-14
- ▶ 研究关注：Sanofi synthesizes new ERK5 inhibitors 2026-05-14
- ▶ 研究关注：Andzonbio2 enters neuroinflammation collaboration 2026-05-14
- ▶ 研究关注：QW-5-70 exhibits antitumor activity in multidrug-resistant tumors 2026-05-14
- ▶ 研究关注：PRMT5 inhibitors detailed in Gilead Sciences patent 2026-05-14
- ▶ 研究关注：Sironax patents new SARM1 inhibitors 2026-05-14
- ▶ 研究关注：Henlius’ HLX-48 for solid tumors cleared for clinic in Australia 2026-05-14
- ▶ 研究关注：Advancing the 'best of both' – BMS, Hengrui enter $15.2B deal 2026-05-14
- ▶ 研究关注：Loss of androgens tied to faster glioblastoma growth 2026-05-14
- ▶ 研究关注：Live SMT enables discovery of RUVBL inhibitors 2026-05-14
- ▶ 研究关注：Visualizing Receptor Transport Within Neurons via Transcytosis 2026-05-13
- ▶ 研究关注：BMS, Hengrui Pharma Partner on 13 Programs in Up-to-$15.2B Collaboration 2026-05-13
- ▶ 研究关注：ASGCT President Terry Flotte Touts Rare Disease Initiatives as His Term Ends 2026-05-13
- ▶ 研究关注：Synthesizing a Natural Sunscreen and Antioxidant in E. coli 2026-05-13
- ▶ 研究关注：ApexGO: AI-Driven Approach to Faster Antibiotic Discovery 2026-05-13
- ▶ 研究关注：Why AI Alone Isn’t Enough for Oligonucleotide Discovery 2026-05-13
- ▶ 研究关注：Cellares and ProTgen Automate Manufacturing of Progenitor T-Cell Therapy for Blood Cancer 2026-05-13
- ▶ 研究关注：FDA’s leadership void leaves biotech with renewed ‘uncertainty’ 2026-05-13
- ▶ 研究关注：Adopting Creative Chemistry to Optimize Bioprocessing Workflow 2026-05-13
- ▶ 研究关注：Yeast We Can Cut Costs By Optimizing Cell-Free Expression Systems 2026-05-13
- ▶ 研究关注：Operator Protection as Core Design Principle for ADC Bioprocessing 2026-05-13
- ▶ 研究关注：Technique Yields Uniform, High-Quality, EVs at Scale 2026-05-13
- ▶ 研究关注：Life sciences ‘sweet’ opportunity in US-China talks 2026-05-13
- ▶ 研究关注：In the mix post-Ventyx, more NLRP3s to seize? 2026-05-13
- ▶ 研究关注：Beone’s BCL2 drug Beqalzi wins FDA nod in mantle cell lymphoma 2026-05-13
- ▶ 研究关注：Nvision secures $55 million, with backing from Abbott 2026-05-13
- ▶ 研究关注：Lilly data point to ‘maintenance’ strategies for GLP-1 weight loss 2026-05-13
- ▶ 研究关注：Nvision secures $55 million, with backing from Abbott 2026-05-13
- ▶ 研究关注：Regulatory actions for May 13, 2026 2026-05-13
- ▶ 研究关注：Financings for May 13, 2026 2026-05-13
- ▶ 研究关注：Other news to note for May 13, 2026 2026-05-13
- ▶ 研究关注：Appointments and advancements for May 13, 2026 2026-05-13
- ▶ 研究关注：Daewoong nabs Innovo’s preclinical IBD asset in ₩663B deal 2026-05-13
- ▶ 研究关注：In the clinic for May 13, 2026 2026-05-13
- ▶ 研究关注：“It Was Not a Cure”: Musunuru Cautions ASGCT on Baby KJ Promise 2026-05-13
- ▶ 研究关注：Assertio accepts new buyout bid; AI biotech Isomorphic banks $2B 2026-05-13
- ▶ 研究关注：ASGCT 2026: Victoria Gray Roadshow Returns to Boston 2026-05-13
- ▶ 研究关注：ASGCT 2026: Circular RNA, the new beast in gene and cell therapy 2026-05-13
- ▶ 研究关注：AOP Health and VRG Therapeutics partner on immunology program 2026-05-13
- ▶ 研究关注：Dewpoint Therapeutics discovers new β-catenin modulators 2026-05-13
- ▶ 研究关注：Pheast presents data on CDH1/Nectin-4-targeted ADC PHST-677 2026-05-13
- ▶ 研究关注：Boehringer Ingelheim licenses Immunitas antibody program 2026-05-13
- ▶ 研究关注：Aeovian Pharmaceuticals synthesizes new CD38 inhibitors 2026-05-13
- ▶ 研究关注：Shanghai Allink Biotherapeutics patents anti-EGFR/MET bispecific ADCs 2026-05-13
- ▶ 研究关注：Foghorn Therapeutics discloses new EP300 degradation inducers 2026-05-13
- ▶ 研究关注：Novel PROTAC degrader targeting SAMHD1 disclosed 2026-05-13
- ▶ 研究关注：BTX-001 enables single-dose treatment for geographic atrophy 2026-05-13
- ▶ 研究关注：Phrontline Biopharma details new B7-H3/EGFR bispecific ADCs 2026-05-13
- ▶ 研究关注：Loss of androgens tied to faster glioblastoma growth 2026-05-13
- ▶ 研究关注：Simcere’s SCR-A019 shows promise for mesothelin-expressing tumors 2026-05-13
- ▶ 研究关注：Tracking hantavirus across the globe 2026-05-13
- ▶ 研究关注：[Podcast] Closing the Distance in Cancer Care 2026-05-13
- ▶ 研究关注：Gene Therapy ETX101 Improves Seizures and Neurodevelopment in Dravet Syndrome in Phase I/II 2026-05-13
- ▶ 研究关注：10x Genomics, Harvard Target Element’s Multiomics Platform in Patent Lawsuit 2026-05-13
- ▶ 研究关注：AAVs in Focus: Practical Approaches to Capsid Analytics and Plasmid DNA Control 2026-05-12
- ▶ 研究关注：Brain Histamine Map Links Genetic Factors to Mental Health and Psychiatric Disorders 2026-05-12
- ▶ 研究关注：Acute Myeloid Leukemia Therapy Improved by CRISPR Stem Cell Transplant 2026-05-12
- ▶ 研究关注：FDA chief Marty Makary resigns from agency, ending tumultuous tenure 2026-05-12
- ▶ 研究关注：Arvinas, Pfizer find new partner for ‘Protac’ breast cancer drug 2026-05-12
- ▶ 研究关注：Makary out at the FDA 2026-05-12
- ▶ 研究关注：Commerce gives Rx companies 30 days to submit US onshoring plans 2026-05-12
- ▶ 研究关注：Coming through on Veppanu with back-loaded Rigel deal 2026-05-12
- ▶ 研究关注：GSK licenses siRNA asset in $1B deal for Siranbio 2026-05-12
- ▶ 研究关注：Multiple appearances on Priority Watch List leading to action? 2026-05-12
- ▶ 研究关注：Appointments and advancements for May 12, 2026 2026-05-12
- ▶ 研究关注：China med-tech raises: Star Sports’ $105M IPO; Cofoe nabs $133M 2026-05-12
- ▶ 研究关注：In the clinic for May 12, 2026 2026-05-12
- ▶ 研究关注：Advancing the 'best of both' – BMS, Hengrui enter $15.2B deal 2026-05-12
- ▶ 研究关注：MHRA sets out proposal to redefine gene therapies 2026-05-12
- ▶ 研究关注：Kailera's record IPO headlines strong April for biopharma financings 2026-05-12
- ▶ 研究关注：Follow-ons hit 7-year high, lead med-tech's $10B start to 2026 2026-05-12
- ▶ 研究关注：Regulatory actions for May 12, 2026 2026-05-12
- ▶ 研究关注：Roche secures CE mark for Alzheimer’s blood test 2026-05-12
- ▶ 研究关注：Curacle, Memento ink $1B deal for ocular TIE2/VEGF bispecific 2026-05-12
- ▶ 研究关注：APAC monitors hantavirus as Singapore isolates 2 from cruise ship 2026-05-12
- ▶ 研究关注：Metis Techbio, Impact Tx cleared for Hong Kong IPOs 2026-05-12
- ▶ 研究关注：Other news to note for May 12, 2026 2026-05-12
- ▶ 研究关注：Veppanu deal between Rigel and Arvinas, Pfizer worth up to $445M 2026-05-12
- ▶ 研究关注：TRPM4 antagonists disclosed in Universitätsklinikum Hamburg-Eppendorf patent 2026-05-12
- ▶ 研究关注：Funding at Infex Therapeutics to advance anti-infectives 2026-05-12
- ▶ 研究关注：OPGx-BEST1 restores BEST1 expression in retinal cells 2026-05-12
- ▶ 研究关注：Fractyl Health’s RJVA-001 cleared to enter clinic in Netherlands 2026-05-12
- ▶ 研究关注：Guardian Biosciences identifies new compounds for TBI 2026-05-12
- ▶ 研究关注：Tango Therapeutics patents new HBS1L degradation inducers 2026-05-12
- ▶ 研究关注：Curacle, Memento ink $1B deal for ocular TIE2/VEGF bispecific 2026-05-12
- ▶ 研究关注：Fibrobiologics explores use of fibroblast platform for hantavirus 2026-05-12
- ▶ 研究关注：First cruise ship hantavirus genome points to zoonotic spillover 2026-05-12
- ▶ 研究关注：JUV-161 reverses structural and functional muscle decline 2026-05-12
- ▶ 研究关注：Zhongshan Institute for Drug Discovery synthesizes YAP1/TEAD interaction inhibitors 2026-05-12
- ▶ 研究关注：HEC Pharma presents oral small-molecule PD-L1 inhibitor 2026-05-12
- ▶ 研究关注：Architect Therapeutics reports new CDK2 inhibitors 2026-05-12
- ▶ 研究关注：Two-step HIV vaccine induces broadly neutralizing antibodies 2026-05-12
- ▶ 研究关注：Bristol Myers, Hengrui join forces in drugmaking alliance worth up to $15.2 billion 2026-05-12
- ▶ 研究关注：In the clinic for May 12, 2026 2026-05-12
- ▶ 研究关注：Regulatory actions for May 12, 2026 2026-05-12
- ▶ 研究关注：Other news to note for May 12, 2026 2026-05-12
- ▶ 研究关注：A year after Vertex’s big launch, pain drug research faces a pivotal moment 2026-05-12
- ▶ 研究关注：Stable Producer Cell Line Generation Platform Adds to VIVEbiotech’s Lentiviral Vector Manufacturing Capabilities 2026-05-12
- ▶ 研究关注：Cholesterol Drug May Weaken Ovarian Cancer’s Metastatic Defense 2026-05-12
- ▶ 研究关注：How HIV-1 Develops Resistance to Broadly Neutralizing Antibodies 2026-05-11
- ▶ 研究关注：Genewiz Launches Gene Synthesis 2.0 2026-05-11
- ▶ 研究关注：MBX highlights early data for monthly obesity drug MBX-4291 2026-05-11
- ▶ 研究关注：Other news to note for May 11, 2026 2026-05-11
- ▶ 研究关注：Appointments and advancements for May 11, 2026 2026-05-11
- ▶ 研究关注：Regulatory actions for May 11, 2026 2026-05-11
- ▶ 研究关注：In the clinic for May 11, 2026 2026-05-11
- ▶ 研究关注：Financings for May 11, 2026 2026-05-11
- ▶ 研究关注：FDA pregnancy safety guidance evolves with the science 2026-05-11
- ▶ 研究关注：Bright Uro secures FDA approval for abdominal sensor 2026-05-11
- ▶ 研究关注：Curacle, Memento ink $1B deal for ocular TIE2/VEGF bispecific 2026-05-11
- ▶ 研究关注：First cruise ship hantavirus genome points to zoonotic spillover 2026-05-11
- ▶ 研究关注：GSK cuts deal with Sino to broaden reach of hepatitis B drug 2026-05-11
- ▶ 研究关注：RegVelo AI Model Predicts Cell Fate, Tackles Developmental Disorders and Cancer 2026-05-11
- ▶ 研究关注：ICYMI: Week in review, May 4-8, 2026 2026-05-11
- ▶ 研究关注：First cruise ship hantavirus genome points to zoonotic spillover 2026-05-11
- ▶ 研究关注：Biggest gainers and losers for May 4-8, 2026 2026-05-11
- ▶ 研究关注：Inhibrx delivers ‘differentiated’ cancer drug data; Fractyl starts diabetes gene therapy trial 2026-05-11
- ▶ 研究关注：Biotech layoffs are easing, but is the worst over? 2026-05-11
- ▶ 研究关注：Boyuan Pharmaceutical prepares new HSV inhibitors 2026-05-11
- ▶ 研究关注：Shanghai Jeyou Pharmaceutical patents LGALS3 inhibitors 2026-05-11
- ▶ 研究关注：Mabwell’s 9MW5211 gains IND clearance for IBD 2026-05-11
- ▶ 研究关注：Traws Pharma to advance hantavirus candidates 2026-05-11
- ▶ 研究关注：Hefei Shengpu Pharmaceutical synthesizes new GTPase KRAS mutant inhibitors 2026-05-11
- ▶ 研究关注：Next-generation PLpro inhibitor for SARS-CoV-2 divulged 2026-05-11
- ▶ 研究关注：First long-acting, intra-articular multikinase inhibitor for OA 2026-05-11
- ▶ 研究关注：ASO therapy prevents hydrocephalus in a monogenic syndrome model 2026-05-11
- ▶ 研究关注：Yantai Rongchang Pharmaceutical reports new KRAS mutant inhibitors 2026-05-11
- ▶ 研究关注：Antimicrobial compounds revealed in University of Hong Kong patent 2026-05-11
- ▶ 研究关注：Soley Therapeutics reports data on new CKAP2 modulator STX-6398 2026-05-11
- ▶ 研究关注：Alzheimer’s, beyond the brain 2026-05-11
- ▶ 研究关注：In vivo mRNA gene therapy platform reprograms cytotoxic T cells 2026-05-11
- ▶ 研究关注：Singlomics’ DXP-106 shows robust results in preclinical setting 2026-05-11
- ▶ 研究关注：The capacity crunch in biopharma is a location problem 2026-05-11
- ▶ 研究关注：Precision in motion: Decoding the critical operations behind the logistics of next-generation cell and gene therapies 2026-05-11
- ▶ 研究关注：StockWatch: enGene Shares Crater on Declines in Complete Response Rates to Bladder Cancer Therapy 2026-05-11
- ▶ 研究关注：Diabetes Drug Metformin’s Blood Glucose-Lowering Effects Tied to Action on Gut Cells 2026-05-10
- ▶ 研究关注：How Digital Orchestration Is Redefining Regulatory Infrastructure for Cell and Gene Therapy 2026-05-08
- ▶ 研究关注：BioWorld and Nasdaq stock indices 2026-05-08
- ▶ 研究关注：Biopharma money raised: Jan. 1-May 7, 2026 2026-05-08
- ▶ 研究关注：Money raised by biopharma 2026-05-08
- ▶ 研究关注：Biopharma money raised by month in 2026 (US$M) 2026-05-08
- ▶ 研究关注：Remembering J. Craig Venter, PhD 2026-05-08
- ▶ 研究关注：Follow-ons hit 7-year high, lead med-tech's $10B start to 2026 2026-05-08
- ▶ 研究关注：Odyssey’s IPO, placement brings $304M to lead drugs in IBD, lupus 2026-05-08
- ▶ 研究关注：Budo judo moves aplenty for Climb in autoimmune 2026-05-08
- ▶ 研究关注：Mobia debuts on Nasdaq to bring stroke therapy to more patients 2026-05-08
- ▶ 研究关注：APAC monitors hantavirus as Singapore isolates 2 from cruise ship 2026-05-08
- ▶ 研究关注：Scarlet raises $4M to take manufactured red blood cells into clinic 2026-05-08
- ▶ 研究关注：In vivo mRNA gene therapy platform reprograms cytotoxic T cells 2026-05-08
- ▶ 研究关注：Regulatory actions for May 8, 2026 2026-05-08
- ▶ 研究关注：Other news to note for May 8, 2026 2026-05-08
- ▶ 研究关注：Appointments and advancements for May 8, 2026 2026-05-08
- ▶ 研究关注：In the clinic for May 8, 2026 2026-05-08
- ▶ 研究关注：Financings for May 8, 2026 2026-05-08
- ▶ 研究关注：Lilly to invest extra $4.5B across Indiana manufacturing 2026-05-08
- ▶ 研究关注：ASGCT CEO David Barrett Previews the Upcoming Conference in Boston 2026-05-08
- ▶ 研究关注：Budoprutug in Climb spotlight for autoimmune indications 2026-05-08
- ▶ 研究关注：ParcelBio Unveils Programmable mRNA Platform Backed by $13M Financing 2026-05-08
- ▶ 研究关注：FDA to reevaluate spurned cell therapy; Under-the-skin Leqembi review extended 2026-05-08
- ▶ 研究关注：Gene Therapy Briefs: Regeneron Wins FDA Approval for First Neurosensory Gene Therapy 2026-05-08
- ▶ 研究关注：Lilly, Gilead lead pharma’s M&A boom 2026-05-08
- ▶ 研究关注：ASGCT Honors Mohamed Abou‑el‑Enein as Outstanding New Investigator 2026-05-08
- ▶ 研究关注：FDA clears IND for Harbour Biomed’s HBM-7004 2026-05-08
- ▶ 研究关注：Hangzhou Bio Sincerity Pharma-Tech identifies new exportin-1 receptor antagonists 2026-05-08
- ▶ 研究关注：Treeline Biosciences patents new RAS inhibitors 2026-05-08
- ▶ 研究关注：Impact Therapeutics discovers new Wee1 inhibitors 2026-05-08
- ▶ 研究关注：Hantavirus is ‘sentinel’ more than acute pandemic threat 2026-05-08
- ▶ 研究关注：BD-200 is strong dual-targeting ADC candidate for cancer 2026-05-08
- ▶ 研究关注：New assay for drug discovery against chemo-induced peripheral neuropathy 2026-05-08
- ▶ 研究关注：University of California discloses new PRKACA-targeting PROTACs 2026-05-08
- ▶ 研究关注：Seed financing at Parcelbio to advance mRNA medicines 2026-05-08
- ▶ 研究关注：Shanghai Ailux Biotechnology synthesizes FGFR2-targeting ADCs 2026-05-08
- ▶ 研究关注：Takeda’s anti-CCR8 ADC shows potent antitumor activity 2026-05-08
- ▶ 研究关注：Hepatitis A vaccine nonclinical efficacy can be tested in IFN receptor KO mice 2026-05-08
- ▶ 研究关注：Arrivent’s MUC16/NaPi2b-targeted ADC gains IND clearance 2026-05-08
- ▶ 研究关注：Two-step HIV vaccine induces broadly neutralizing antibodies 2026-05-08
- ▶ 研究关注：Odyssey, on second try, snags $279M in an IPO 2026-05-08
- ▶ 研究关注：Macrophages Use Cell Volume Changes to Sense Danger and Amplify Inflammation 2026-05-07
- ▶ 研究关注：From Sequence to Patient in Under 12 Months: A Case Study in Advancing Complex Cancer Immunotherapies 2026-05-07
- ▶ 研究关注：G-Link CAR-T Delivery Platform Showcased at ASGCT 2026-05-07
- ▶ 研究关注：Sarepta tumbles as its gene therapy sales decline further 2026-05-07
- ▶ 研究关注：Human Antibodies Identified That Have Potential To Prevent and Treat Measles Virus 2026-05-07
- ▶ 研究关注：Oral Small-Molecule GLP-1s Linked to Deep Brain Activity and Reduced Cravings in Mice 2026-05-07
- ▶ 研究关注：Digital PCR Playbook: Applications and Challenges Across Research and Clinical Labs 2026-05-07
1 / 34